Pipeline

Our pipelines embody our dedication to groundbreaking healthcare advancements. Focused on pivotal areas in disease management, our projects aim to significantly improve patient outcomes. Here, we present a vision of the future in medical innovation, catering to the needs of patients, physicians, oncologists, and administrators.

1. Multi Cancer Early Detection (MCED):
Early Intervention Screening

We have successfully completed multiple international multi cancer early detection studies involving several thousand participants. Recently, the test was validated in a clinical laboratory and has shown incredible results with never-before seen stage I results. A major MCED study was published at the ASCO Annual Meeting 2025. A blinded validation study that confirmed the results is yet to be published. Select clinical partners might be considered for collaboration.

2. Pancreatic Cancer Early Detection:
Targeting the Silent Killer

Our pancreatic cancer early detection test has made significant strides in identifying this challenging disease in its early stages. Wholomics has conducted multiple clinical studies that have been published at the ASCO GI Symposium 2024 and the ASCO Annual Meeting 2024. Following the substantial progress, we are now actively engaged in clinical trials in high-risk patients. Leveraging cutting-edge multiomic biomarkers and AI , we are gearing up to role out the pancreatic cancer detection test for the patients with the highest need.

3. Ovarian Cancer Early Detection:
Targeting a Deadly Cancer

Ovarian cancer remains one of the deadliest cancers because it is usually diagnosed too late. Wholomics has developed a targeted early detection blood test that addresses this gap. In multiple clinical studies, our technology demonstrated unprecedented accuracy, detecting ovarian cancer at its earliest and most treatable stages. Select clinical partners might be considered for collaboration.

4. Liver Cancer Early Detection:
Targeting a Global Health Challenge

Liver cancer is a growing global health challenge, particularly in patients with chronic liver disease or cirrhosis. Wholomics is developing a dedicated early detection test to serve this high-risk population. Preliminary study results have been astounding, showing the potential to identify liver cancer far earlier than current imaging or markers allow. Blinded validation studies are in preparation, and clinical collaborations are actively being pursued.

5. Cancer Monitoring:
Continous Care, Enhanced Outcomes

Our cancer monitoring project is dedicated to providing ongoing surveillance for patients in remission or undergoing treatment. This vigilant approach ensures timely detection of recurrence or progression, enabling prompt intervention. Currently we are planning the studies and developing the technology to monitor cancer patients. A first pilot study is ongoing and further validation is planned.

6. Precision Oncology:
Personalized Medicine for Tailored Therapies

This project is at the cutting edge of precision medicine, using predictive models to determine individual responses to various cancer treatments. This helps in customizing patient care for maximum efficacy and minimal side effects. Wholomics is currently in the planning phase of this study but is allready conducting a pilot study on multiple hundred patients.

7. Precision Neurology:
Proactive Approach to Neuro Health

Early detection is crucial in managing neuro-degenerative diseases. Our project focuses on identifying early markers of conditions like Alzheimer's and Parkinson's, offering hope for earlier intervention and better management strategies. Wholomics is currently looking for partners in the area of neurodegenerative diseases.

Become a Partner

Wholomics is considering select clinical partners.
Fill out the form below and one of our staff members will get back to you.